Skip to content
Search

Latest Stories

NHS hospitals alerted about life-saving drug shortage

NHS hospitals alerted about life-saving drug shortage

Hospitals  advised to place urgent orders for unlicensed imports of salbutamol nebuliser liquid

The Department of Health and Social Care (DHSC) and NHS England last month issued a “safety critical” national patient safety alert, warning about the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues.


NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain “out of stock” until mid-April 2024.

As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers.

It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could’t meet the increased demand.

Hospitals were advised to “liaise with local pharmacy teams and place urgent orders for unlicensed imports of salbutamol nebuliser liquid.”

Healthcare providers were directed to use high-dose salbutamol pressurised metered-dose inhaler (pMDI) in patients with mild to moderate asthma attacks or chronic obstructive pulmonary disease (COPD), and prescribe nebuliser liquids where the inhaler is not appropriate.

Supplies of salbutamol nebuliser liquids should be prioritised for “acute, severe exacerbations of COPD and asthma; bronchospasm secondary to refractory anaphylaxis; in patients who cannot use a pMDI; other conditions where the use of high-dose salbutamol pMDI via a spacer is inappropriate e.g. moderate to severe hyperkalaemia.”

In January, the British Association of Dermatologists (BAD)cautioned that the shortage of medicines was contributing to the outbreak of scabies in the UK. Both permethrin 5% cream and malathion liquid, two main topical treatments for scabies, were reported to be in limited supply since May 2023.

According to the British Generic Manufacturers Association (BGMA), more than 100 products were facing supply problems last year, the highest on record in the UK, and more than double the number recorded at the start of 2022.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less